Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iron oxide nanochains are a specialized form of superparamagnetic iron oxide nanoparticles (SPIONs) engineered into chain-like assemblies. These structures are designed to enhance magnetic properties and cellular uptake compared to conventional spherical or cubic SPIONs. Iron oxide nanochains exhibit superior sensitivity in magnetic particle imaging (MPI), making them promising tracers for non-invasive cancer diagnostics—particularly breast cancer—and for monitoring disease progression. When conjugated with targeting ligands such as RGD peptides, they can selectively accumulate in tumor tissue. Their mechanism of action is based on their superparamagnetic behavior, which allows them to serve as contrast agents for imaging modalities like MPI and MRI and as vehicles for targeted drug delivery or hyperthermia therapy when exposed to external magnetic fields. The unique shape and assembly of the chains improve both their biocompatibility and efficacy in biomedical applications[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iron oxide nanochains.